Smoking and short-term response to intravitreal anti-Vascular Endothelial Growth Factor injections in neovascular age-related macular degeneration
Journal Français d'Ophtalmologie · 2024
DOI: 10.1016/j.jfo.2023.04.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal Français d'Ophtalmologie, 2024. Verfasst von S Caspers und 3 weiteren Autor:innen. Beteiligte Einrichtung: Service d'ophtalmologie, CHU Brugmann, université libre de Bruxelles, place Van Gehuchten 4, 1020 Brussels, Belgium. Electronic address: sophie.caspe…. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Wet Macular Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the role of smoking status on the response to three monthly intravitreal anti-Vascular Endothelial Growth Factor (anti-VEGF) injections in treatment-naive neovascular AMD (nAMD) patients. METHODS: We conducted a single-center, retrospective, case-control cohort study in Belgium. RESULTS: Intravitreal treatment (IVT) was performed in 147 eyes of 131 patients, including 92 females (70%). Mean age at the time of the first IVT was 79±9 years. Seventeen patients (13%) were actively smoking at the time of the anti-VEGF IVT. On average, active smokers were 11 years younger than non-smokers when starting IVT treatment. They also showed more frequent subretinal fluid than non-smokers (94% vs. 65%). Mann-Whitney analyses comparing change in central macular thickness and change in logarithm of the minimum angle of resolution visual acuity between active smokers and non-smokers showed no significant difference in treatment response between both groups. Likewise, no significant difference was found when comparing treatment response between patients with less than 10 pack-years (PY) (including never-smokers) and patients with over 10 PY. In a binary logistic regression model, male patients responded worse to anti-VEGF IVT than their female counterparts, with an odds ratio (OR) of 0.27 for good response. This was the only statistically significant predictor of treatment response. CONCLUSION: Our study failed to demonstrate an effect of smoking on the short-term treatment response to anti-VEGF in nAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'ophtalmologie, CHU Brugmann, université libre de Bruxelles, place Van Gehuchten 4, 1020 Brussels, Belgium. Electronic address: sophie.caspers@chu-brugmann.be.
- Service d'ophtalmologie, CHU Brugmann, université libre de Bruxelles, place Van Gehuchten 4, 1020 Brussels, Belgium.
Zitieren
APA
Caspers, S., Abramowicz, S., Pasteels, B., & Postelmans, L. (2024). Smoking and short-term response to intravitreal anti-Vascular Endothelial Growth Factor injections in neovascular age-related macular degeneration. Journal Français d'Ophtalmologie. https://doi.org/10.1016/j.jfo.2023.04.010
Vancouver
Caspers S, Abramowicz S, Pasteels B, Postelmans L. Smoking and short-term response to intravitreal anti-Vascular Endothelial Growth Factor injections in neovascular age-related macular degeneration. Journal Français d'Ophtalmologie. 2024. doi:10.1016/j.jfo.2023.04.010
BibTeX
@article{Caspers2024,
author = {Caspers, S and Abramowicz, S and Pasteels, B and Postelmans, L},
title = {Smoking and short-term response to intravitreal anti-Vascular Endothelial Growth Factor injections in neovascular age-related macular degeneration},
journal = {Journal Français d'Ophtalmologie},
year = {2024},
doi = {10.1016/j.jfo.2023.04.010}
}
EUVIMED